Hiroki Hara

机构：TDK (Japan), Saitama Prefecture, Saitama Cancer Center, Tungaloy Corporation (Japan) · ORCID：0000-0003-3881-9815

发表论文 507 篇 · 总被引 16679 次 · h-index 46

代表论文

• Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High) (2025 · Therapeutic Advances in Medical Oncology · 被引 7)
• Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan (2026 · EClinicalMedicine · 被引 4)
• LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study (2025 · Annals of Oncology · 被引 4)
• EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (2026 · Journal of Clinical Oncology · 被引 3)
• Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109 (2026 · Annals of Surgical Oncology · 被引 3)
• Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study (2025 · Cancer Research Communications · 被引 2)